IM Cannabis Corp. (IMCC) vs Redhill Biopharma Ltd. (RDHL)

IM Cannabis Corp. and Redhill Biopharma Ltd. are both Drug Manufacturers Specialty & Generic companies. Redhill Biopharma Ltd. is the larger, with a market value of $3.8M against $980.0K — 3.9× the size. IM Cannabis Corp. grew revenue faster over the last twelve months: −12.0% against −61.9%. Redhill Biopharma Ltd. has the higher net margin (25.2% vs −38.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, IM Cannabis Corp. leads on 9 and Redhill Biopharma Ltd. on 7.

Valuation

Metric IMCC RDHL Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S 0.01 0.00 2.08
P/B n/m n/m 1.79
Price to free cash flow n/m n/m 16.29
EV/EBITDA 0.01 n/m 12.22
EV/Sales 0.00 6.43 2.87
Earnings yield (13,047.81%) (142,015.51%) (15.94%)
Free cash flow yield (267.31%) (231,394.02%) 0.00%

Profitability

Metric IMCC RDHL Drug Manufacturers Specialty & Generic median
Gross margin 12.62% 35.16% 53.51%
Operating margin (32.88%) 0.00% 0.00%
Net margin (38.92%) 25.20% (2.45%)
Free cash flow margin (1.47%) 0.00% 0.00%
Return on equity 2,280.06% 0.00% (0.80%)
Return on assets (54.20%) 0.00% (1.67%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMCC RDHL Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (11.97%) (61.93%) 5.22%
EPS growth (last fiscal year) 41.95% 97.91% 42.91%
Revenue growth, 5-year CAGR 26.99% (66.15%) 7.24%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMCC RDHL Drug Manufacturers Specialty & Generic median
Debt to equity (0.12) 0.00 0.04
Current ratio 0.56 0.34 2.41
Net debt to EBITDA 0.18 0.53 1.01

Dividend

Metric IMCC RDHL Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric IMCC RDHL Drug Manufacturers Specialty & Generic median
Market cap 980.00k 3.79m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack